These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34572350)

  • 1. Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy.
    Fukuda Y; Sakurada Y; Matsubara M; Hasebe Y; Sugiyama A; Kikushima W; Kashiwagi K
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of one-year outcomes between as-needed brolucizumab and aflibercept for polypoidal choroidal vasculopathy.
    Fukuda Y; Sakurada Y; Matsubara M; Kotoda Y; Kasai Y; Sugiyama A; Kashiwagi K
    Jpn J Ophthalmol; 2023 Jul; 67(4):402-409. PubMed ID: 37289296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal Brolucizumab and Aflibercept for Polypoidal Choroidal Vasculopathy.
    Cho HJ; Kang KH; Yoon W; Lee J; Kim CG; Kim JW
    J Ocul Pharmacol Ther; 2023 Nov; 39(9):653-660. PubMed ID: 37504966
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.
    Ogura Y; Jaffe GJ; Cheung CMG; Kokame GT; Iida T; Takahashi K; Lee WK; Chang AA; Monés J; D'Souza D; Weissgerber G; Gedif K; Koh A
    Br J Ophthalmol; 2022 Jul; 106(7):994-999. PubMed ID: 34301613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching to brolucizumab from aflibercept in age-related macular degeneration with type 1 macular neovascularization and polypoidal choroidal vasculopathy: an 18-month follow-up study.
    Ueda-Consolvo T; Tanigichi A; Numata A; Oiwake T; Nakamura T; Ishida M; Yanagisawa S; Hayashi A
    Graefes Arch Clin Exp Ophthalmol; 2023 Feb; 261(2):345-352. PubMed ID: 35947181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Polyp Regression after Loading Phase with 12-Month Outcomes of Eyes with Polypoidal Choroidal Vasculopathy.
    Kimura M; Sakurada Y; Fukuda Y; Matsubara M; Kotoda Y; Kasai Y; Sugiyama A; Kikushima W; Tsuru DV; Kashiwagi K
    Pharmaceuticals (Basel); 2024 May; 17(6):. PubMed ID: 38931354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.
    Saito M; Kano M; Itagaki K; Ise S; Imaizumi K; Sekiryu T
    Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
    Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
    BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy.
    Jeong S; Sagong M
    Br J Ophthalmol; 2017 Jun; 101(6):758-763. PubMed ID: 27597740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy.
    Cho HJ; Kim KM; Kim HS; Han JI; Kim CG; Lee TG; Kim JW
    Am J Ophthalmol; 2016 May; 165():1-6. PubMed ID: 26921806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Komuku Y; Iwahashi C; Gomi F
    Jpn J Ophthalmol; 2020 May; 64(3):265-270. PubMed ID: 32206935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
    Matsumiya W; Honda S; Otsuka K; Miki A; Nagai T; Imai H; Kusuhara S; Nakamura M
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):541-548. PubMed ID: 27687988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab.
    Saito M; Kano M; Itagaki K; Oguchi Y; Sekiryu T
    Retina; 2014 Nov; 34(11):2192-201. PubMed ID: 25077530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy.
    Hosokawa M; Shiraga F; Yamashita A; Shiragami C; Ono A; Shirakata Y; Kimura S; Shiode Y; Kawata T; Hosogi M; Fujiwara A; Morizane Y
    Br J Ophthalmol; 2015 Aug; 99(8):1087-91. PubMed ID: 25712826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year outcomes of intravitreal brolucizumab injections in patients with polypoidal choroidal vasculopathy.
    Ito A; Maruyama-Inoue M; Kitajima Y; Ikeda S; Inoue T; Kadonosono K
    Sci Rep; 2022 May; 12(1):7987. PubMed ID: 35568780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optic disk melanocytoma associated with polypoidal choroidal vasculopathy lesions, after combination treatment of photodynamic therapy and intavitreal aflibercept (Eylea), a case report.
    Rouvas A; Gouliopoulos NS; Moschos MM; Theodossiadis P
    BMC Ophthalmol; 2018 Oct; 18(1):267. PubMed ID: 30309335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ONE-YEAR RESULTS OF INTRAVITREAL AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Hara C; Sawa M; Sayanagi K; Nishida K
    Retina; 2016 Jan; 36(1):37-45. PubMed ID: 26383709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
    Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
    Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study.
    Lee JE; Shin JP; Kim HW; Chang W; Kim YC; Lee SJ; Chung IY; Lee JE;
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):493-502. PubMed ID: 27628062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to brolucizumab treatment for refractory serous pigment epithelial detachment secondary to polypoidal choroidal vasculopathy.
    Nam SW; Byun Z; Ham DI; Kong M
    BMC Ophthalmol; 2022 Dec; 22(1):485. PubMed ID: 36514022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.